Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Tang-Du Hospital is the lead sponsor of 50 current clinical trials in our China register. 33 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Adebrelimab, Carboplatin and Etoposide. The most-studied condition is Esophageal Squamous Cell Carcinoma.

ClinicalTrials.gov trials by status

Recruiting3366%
Not yet open1224%
Active, closed48%
By invitation12%

Trials by phase

Phase 21938%
Not applicable1224%
Observational918%
Phase 1/248%
Phase 424%
Phase 324%
Phase 124%

Clinical trials sponsored by Tang-Du Hospital

50 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer NCT06128252 · ClinicalTrials.gov ↗ · Gastric Cancer Drugs: Serplulimab, Xelox	Not applicable	Recruiting	2024-09	China
Intra-arterial Methylprednisolone After Successful Endovascular Thrombectomy Anterior Circulation Large Vessel Occlusion NCT07141303 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke	Phase 3	Recruiting	2025-08	China
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC NCT07385001 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Ivonescimab, Neoadjuvant Drug: Ivonescimab	Phase 1/2	Recruiting	2026-01	China
Multi-Field-Strength MRI Brain Atlas Construction in Healthy Chinese Population NCT07786233 · ClinicalTrials.gov ↗ · Healthy Adult Brain Imaging	Not applicable	Recruiting	2026-07	China
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial NCT06485544 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC) Drugs: Adebrelimab, Etoposide	Phase 2	Recruiting	2024-07	China
Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy NCT07141264 · ClinicalTrials.gov ↗ · SCLC,Extensive Stage Drugs: Adebrelimab, Etoposide	Phase 2	Recruiting	2025-08	China
Ofatumumab in AQP4-IgG Seropositive NMOSD NCT05504694 · ClinicalTrials.gov ↗ · Neuromyelitis Optica Spectrum Disorder Drug: Ofatumumab	Phase 1/2	Recruiting	2022-06	China
Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD) NCT07377305 · ClinicalTrials.gov ↗ · NMO Spectrum Disorder	Not applicable	Recruiting	2025-12	China
TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study NCT04182984 · ClinicalTrials.gov ↗ · Ocular Myasthenia Gravis	Observational	Recruiting	2019-11	China
Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer NCT06467786 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 4	Recruiting	2024-03	China
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer NCT07353723 · ClinicalTrials.gov ↗ · Head & Neck Cancer Drugs: Carboplatin, Nab-paclitaxel, Nimotuzumab	Phase 2	Recruiting	2025-11	China
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC NCT06864624 · ClinicalTrials.gov ↗ · NSCLC Drug: Sunvozertinib	Phase 2	Recruiting	2025-02	China
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis NCT05067348 · ClinicalTrials.gov ↗ · Myasthenia Gravis, Generalized	Phase 2	Recruiting	2022-07	China
Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) NCT07354061 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer) Drug: Ensartinib	Phase 1/2	Recruiting	2026-03	China
Assessment of Brain Cognitive Impairment in Breast Cancer NCT05305092 · ClinicalTrials.gov ↗ · Breast Cancer, Chemo-brain, Endocrine Therapy	Observational	Recruiting	2022-05	China
Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study NCT06896747 · ClinicalTrials.gov ↗ · Thin Endometrial Lining, Female Infertility, Intrauterine Adhesions Drug: Platelet-rich plasma	Phase 1/2	Recruiting	2025-02	China
Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50% NCT07596121 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer) Drug: Serplulimab	Phase 2	Recruiting	2026-05	China
Safety and Efficacy Analysis of Stent-assisted Coil Embolization in the Treatment of Acute Ruptured Intracranial Aneurysms in the Perioperative Period. NCT07683377 · ClinicalTrials.gov ↗ · Ruptured Aneurysm of Intracranial Artery, Stent-Assisted Coiling, Efficacy and Safety	Not applicable	Recruiting	2026-01	China
Assess the Risk of Cerebrovascular Disease NCT04443439 · ClinicalTrials.gov ↗ · Cerebrovascular Disease	Observational	Recruiting	2020-10	China
The Early Warning System for the Diabetic Encephalopathy NCT02420470 · ClinicalTrials.gov ↗ · Diabetes Mellitus Type 2, Mild Cognitive Impairment, Metabolic Syndrome X	Observational	Recruiting	2015-04	China
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell NCT06006650 · ClinicalTrials.gov ↗ · Neoadjuvent, PD-1 Inhibitor, Chemotherapy	Phase 2	Recruiting	2022-08	China
Effect of Semi-elemental Enteral Nutrition on Gastrointestinal Tolerance in Patients With Traumatic Brain Injury. NCT07092423 · ClinicalTrials.gov ↗ · Traumatic Brain Injury, Neurocritical Care, Enteral Feeding Intolerance	Not applicable	Recruiting	2025-05	China
Clinical Value of Saline Infusion Sonohysterography in the Assessment of Cesarean Scar Defects NCT07610668 · ClinicalTrials.gov ↗ · Infertility	Observational	Recruiting	2023-01	China
Adebrelimab + Apatinib in SCLC Maintenance Therapy NCT06475209 · ClinicalTrials.gov ↗ · SCLC Drugs: Adebrelimab, Apatinib	Phase 2	Recruiting	2024-06	China
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC NCT06055738 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer Drugs: Albumin-Bound Paclitaxel, CDDP, Cisplatin	Phase 2	Recruiting	2023-10	China
Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane NCT06644066 · ClinicalTrials.gov ↗ · Lung Cancer	Not applicable	Recruiting	2024-05	China
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC NCT07452601 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	2026-05	China
Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions NCT06065046 · ClinicalTrials.gov ↗ · Traumatic Brain Injury Drug: Baricitinib	Phase 2	Recruiting	2023-11	China
Anxiety and Depression in IBS: A Brain-Gut Axis Study NCT07646834 · ClinicalTrials.gov ↗ · Irritable Bowel Syndrome (IBS), Anxiety, Depression	Observational	Recruiting	2025-12	China
Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility NCT07494877 · ClinicalTrials.gov ↗ · Infertility	Observational	Recruiting	2025-09	China
Intra-arterial Methylprednisolone After Endovascular Thrombectomy NCT07516522 · ClinicalTrials.gov ↗ · Ischemia Stroke, Thrombectomy, Large Vessel Occlusion	Phase 2	Recruiting	2026-03	China
Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial NCT07498374 · ClinicalTrials.gov ↗ · Eosinophilic Chronic Rhinosinusitis With Nasal Polyps	Not applicable	Recruiting	2026-01	China
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study NCT06663059 · ClinicalTrials.gov ↗ · Esophageal Cancer Drug: Adebrelimab	Phase 2	Recruiting	2024-10	China
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial NCT07699770 · Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain Drug: Crisugabalin	Phase 4	Not yet open	2026-06	China
Bristol Stool Scale-Based Care Pathway for Enteral Nutrition-Associated Diarrhea in Critically Ill Patients NCT07683364 · ClinicalTrials.gov ↗ · Critical Illness, Diarrhea	Not applicable	Not yet open	2026-06	China
Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer NCT07538193 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging, Lymphatic Metastasis Drug: Iparomlimab and Tuvonralimab	Not applicable	Not yet open	2026-05	China
Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma NCT07752394 · ClinicalTrials.gov ↗ · Head & Neck Cancer Drugs: Carboplatin, Finotonlimab, Nab-paclitaxel	Phase 2	Not yet open	2026-08	China
Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC NCT07618910 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Not yet open	2026-05	China
Exosome-based Nanoplatform for Ldlr mRNA Delivery in FH NCT05043181 · ClinicalTrials.gov ↗ · Familial Hypercholesterolemia	Phase 1	Not yet open	2021-12	China
Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma NCT07678580 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Not yet open	2026-07	China
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC NCT06475755 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Anti Angiogenesis	Phase 2	Not yet open	2024-06	China
Clinical Trial on the Efficacy and Safety of Biodegradable 3D-Printed Implants in Chest Wall Reconstruction Surgery NCT06977022 · ClinicalTrials.gov ↗ · Chest Wall Tumor	Not applicable	Not yet open	2025-05	China
An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH NCT07528235 · ClinicalTrials.gov ↗ · Intracerebral Hemorrhage, Stroke-Associated Pneumonia (SAP)	Phase 1	Not yet open	2026-05	China
A National Multicenter Study of Etrasimod for the Treatment of Patients With Active UC NCT07705126 · ClinicalTrials.gov ↗ · Ulcerative Colitis (UC) Drug: Etrasimod	Observational	Not yet open	2026-07	China
Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma NCT06952621 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 3	Not yet open	2026-02	China
Predictive Efficacy of Fecal Calprotectin Assay by Magnetic Particle Chemiluminescence for Mucosal Healing in Moderate-to-Severe Ulcerative Colitis Patients Undergoing Initial Biologic Therapy（PRECAL） NCT07721441 · ClinicalTrials.gov ↗ · Ulcerative Colitis (UC)	Observational	By invitation	2026-06	China
Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE) NCT05430802 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drug: Furmonertinib	Phase 2	Active, closed	2022-02	China
fMRI Study of the Neural Mechanism of rTMS in the Treatment of Nicotine Dependence NCT06762535 · ClinicalTrials.gov ↗ · Tobacco Use Disorder, Repetitive Transcranial Magnetic Stimulation	Not applicable	Active, closed	2023-04	China
Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis NCT07071246 · ClinicalTrials.gov ↗ · Treatment Drug: Rituximab	Not applicable	Active, closed	2022-08	China
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC NCT05400070 · ClinicalTrials.gov ↗ · Sintilimab, Lung Cancer, Anlotinib Drugs: Anlotinib, Dexamethasone, Sintilimab	Phase 2	Active, closed	2021-03	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Tang-Du Hospital trials

29 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Tang-Du Hospital trials

68 conditions

Esophageal Squamous Cell Carcinoma4 Head & Neck Cancer2 Esophageal Squamous Cell Carcinoma (ESCC)2 Ulcerative Colitis (UC)2 NSCLC (Non-small Cell Lung Cancer)2 Chemotherapy2 Traumatic Brain Injury2 Infertility2 Lung Cancer2Neuromyelitis Optica Spectrum Disorders (NMOSD)1Neuropathic Pain1Non-small Cell Lung Cancer1 Critical Illness1Diarrhea1Gastric Cancer1Carcinoma, Non-Small-Cell Lung (NSCLC)1Neoplasm Staging1Lymphatic Metastasis1Acute Ischemic Stroke1Ivonescimab1Neoadjuvant1Tobacco Use Disorder1Repetitive Transcranial Magnetic Stimulation1Healthy Adult Brain Imaging1

By trial register

Register	Trials	Recruiting
Clinical trials in China	50	33

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Esophageal Squamous Cell Carcinoma

Sponsor	Trials
Peking University	5
Hebei Medical University Fourth Hospital	4
Shanghai Zhongshan Hospital	4
Anhui Provincial Hospital	4
Zhejiang Cancer Hospital	3
Fujian Medical University Union Hospital	3
Sichuan Cancer Hospital and Research Institute	2
Karolinska University Hospital	1
Shandong Boan Biotechnology	1
Affiliated Cancer Hospital of Shantou University Medical College	1

Sponsors with the most current trials registered for this condition.

Questions about Tang-Du Hospital trials

How many clinical trials does Tang-Du Hospital sponsor?

Tang-Du Hospital is the lead sponsor of 50 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Tang-Du Hospital trials recruiting?

Yes. 33 of its 50 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Tang-Du Hospital testing?

Its current trials name 29 drugs and biologicals as interventions. The most frequent are Adebrelimab (4), Carboplatin (2), Etoposide (2), Nab-paclitaxel (2) and Serplulimab (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Tang-Du Hospital clinical trials